Hologic

Hologic, Inc. engages in the development, manufacture, and supply of diagnostics products, medical imaging systems, and surgical products dedicated to serve the healthcare needs of women. It operates through the following segments: Breast Health, Diagnostics, GYN Surgical, and Skeletal Health. The Breast Health segment includes a portfolio of solutions for breast cancer care for radiology, pathology, and surgery. The Diagnostics segment consists of products used to aid in the screening and diagnosis of human diseases. The GYN Surgical segment involves the NovaSure Endometrial Ablation System, the MyoSure Hysteroscopic Tissue Removal System, and the Fluent Fluid Management System. The Skeletal Health segment covers the Horizon DXA and the Fluoroscan Insight FD mini C-arm. The company was founded by S. David Ellenbogen and Jay A. Stein in 1985 and is headquartered in Marlborough, MA.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Hologic exceeds Q1 earnings, eyes growth in women's health

Hologic's Q1 performance surpassed expectations, driven by strong organic growth and strategic initiatives. The company's commitment to women's health, financial strength, and focus on innovation position it well for future growth. Challenges in Breast Health highlight areas for improvement, while opportunities in new markets and products offer avenues for expansion.

Hologic surpasses Q2 expectations, eyes international growth and women's health

Hologic's Q2 performance exceeded expectations, driven by robust organic revenue growth and strong margins across divisions.
While facing challenges like COVID-related revenue declines and seasonal factors, the company's strategic strengths in women's health and international expansion present growth opportunities.
To sustain growth, Hologic must navigate macro uncertainties, balance growth drivers, and capitalize on opportunities in diagnostics and global expansion.
Overall, Hologic's solid financial results, increased revenue guidance, and strategic initiatives position the company for continued success in the healthcare market.

Hologic excels in Q3 earnings, eyes global growth amid challenges

Hologic delivered strong financial results in Q3 2023, driven by robust revenue growth and strategic product offerings across its divisions.
While facing margin challenges and geopolitical uncertainties, the company remains optimistic about sustaining growth and enhancing profitability through operational improvements.
With a focus on innovation, global expansion, and cautious M&A strategies, Hologic is well-positioned to capitalize on opportunities and navigate challenges in the healthcare market.

Hologic surpasses revenue targets, eyes international growth and strategic M&A

Hologic delivered strong financial performance in Q4 2023, exceeding revenue and EPS targets while emphasizing women's health and innovation.
The company's focus on international growth, strategic capital allocation, and product portfolio strength position it well for continued success.
Challenges in regulatory compliance, M&A decisions, and market dynamics require careful navigation for sustained growth.
Opportunities in international expansion, strategic M&A, and product innovation offer avenues for future growth and market leadership.

Hologic surpasses Q1 revenue expectations, eyes international growth opportunities

Hologic delivered strong Q1 2024 results, exceeding revenue guidance and showcasing robust financial performance with organic growth of 5.2% ex-COVID.
The company's focus on innovation, market expansion, and strong customer relationships positions it well for continued growth and success beyond COVID testing.
While facing challenges such as tough comps in Q2 and potential tax rate impacts, Hologic's disciplined growth strategies and commitment to transformative initiatives offer opportunities for future expansion.
With a strong emphasis on AI capabilities, market expansion, and strategic M&A, Hologic is poised for sustained growth and market leadership in the healthcare sector.

Hologic beats Q2 revenue targets, eyes international growth opportunities

Hologic exceeded revenue and EPS expectations in Q2 2024, showcasing growth in key business segments.
While facing challenges in certain revenue streams, the company is focused on international expansion and margin improvement.
Opportunities lie in leveraging international growth, strategic acquisitions, and product utilization trends.
Overall, Hologic's performance reflects resilience post-COVID and strategic focus on innovation and market positioning.

Hologic surpasses Q3 revenue expectations, eyes international growth opportunities

Hologic's Q3 performance reflects resilience and growth across key business segments, supported by strategic investments and operational excellence. With a focus on innovation and international expansion, the company is well-positioned for sustained growth and value creation in the evolving healthcare landscape.

Hologic exceeds Q4 earnings, eyes international growth and new products

Hologic's Q4 2024 earnings call showcased strong performance, strategic strengths, and growth opportunities. Challenges include maintaining margin expansion and balancing international growth. The company's focus on durable revenue base and new product pipeline sets a positive outlook for fiscal 2025.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Hologic, Inc. engages in the development, manufacture, and supply of diagnostics products, medical imaging systems, and surgical products, that focuses on women’s health and well-being through early detection and treatment. It operates through the following segments: Breast Health, Diagnostics, GYN Surgical, and Skeletal Health. The Breast Health segment is involved in a portfolio of solutions for breast cancer care primarily in the areas of radiology, breast surgery, pathology and treatment. The Diagnostics segment offers a range of products, which are used primarily to aid in the screening and diagnosis of human diseases. The GYN Surgical segment is involved in hysteroscopic endometrial ablation systems, tissue removal systems, fluid management systems, and laparoscopic tissue ablation systems and tools. The Skeletal Health segment covers the Horizon DXA and the Fluoroscan Insight FD mini C-arm. The company was founded by S. David Ellenbogen and Jay A. Stein in 1985 and is headquartered in Marlborough, MA.

Advanced Semiconductor Engineering

Goldman Sachs

Honda

ArcelorMittal

Owens & Minor

P/B ratio is emerging as a convenient tool for identifying low-priced stocks that have high growth prospects. PVH Corp. (PVH), Honda Motor (HMC), Owens & Minor (OMI), ArcelorMittal (MT), Hologic (HOLX), ASE Technology Holding (ASX) and Goldman Sachs (GS) are good stocks to add.

Buy These 7 Stocks With Low P/B Ratio to Boost Returns

On Wednesday, Hologic got an upgrade for its IBD SmartSelect Composite Rating from 94 to 96. The post Hologic Stock Sees Composite Rating Climb To Lofty 96 appeared first on Investor's Business Daily.

Hologic Stock Sees Composite Rating Climb To Lofty 96

On Wednesday, Hologic got an upgrade for its IBD SmartSelect Composite Rating from 94 to 96. The post Top-Rated Stocks: Hologic Sees Composite Rating Climb To 96 appeared first on Investor's Business Daily.

Top-Rated Stocks: Hologic Sees Composite Rating Climb To 96

Hologic (HOLX) has been struggling lately, but the selling pressure may be coming to an end soon

Hologic (HOLX) Sees Hammer Chart Pattern: Time to Buy?

Camping World Hlds

Westlake Chemical

Top Ranked Growth Stocks to Buy for March 12th

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Should Value Investors Buy Hologic (HOLX) Stock?

Hologic (HOLX) is working to develop a global women's health index through Gallup's World Poll to improve quality of life and life expectancy of women worldwide.

Hologic (HOLX) Partners With Gallup on Women's Health Index

MARLBOROUGH, Mass.--(BUSINESS WIRE)-- #gallup--Hologic Announces Multi-year Initiative to Improve Quality of Life and Life Expectancy of Women Worldwide

Hologic Announces Multi-year Initiative to Improve Quality of Life and Life Expectancy of Women Worldwide

Owens Corning

Tempur Sealy International

Universal Electronics

Top Ranked Growth Stocks to Buy for March 5th

Hologic saw its IBD SmartSelect Composite Rating rise to 98 Friday, up from 94 the day before. The post Composite Rating For Hologic Rises To 98 appeared first on Investor's Business Daily.

Composite Rating For Hologic Rises To 98

Semler Scientific

HOLX vs. SMLR: Which Stock Is the Better Value Option?

HOLX or SMLR: Which Is the Better Value Stock Right Now?

Hologic (HOLX) strengthens international capabilities and expands diagnostics arm across test menu, customer segments and geography with recent acquisition.

Hologic (HOLX) Boosts Diagnostics Portfolio With New Buyout

MARLBOROUGH, Mass.--(BUSINESS WIRE)-- #acquisition--Hologic Acquires European Molecular Diagnostic Company Diagenode for Approximately $159 Million

Hologic Acquires European Molecular Diagnostic Company Diagenode for Approximately $159 Million

MARLBOROUGH, Mass.--(BUSINESS WIRE)--Hologic Completes Acquisition of Biotheranostics, Enabling Entry into Growing Oncology Market

Hologic Completes Acquisition of Biotheranostics, Enabling Entry into Growing Oncology Market

Hologic (HOLX) could produce exceptional returns because of its solid growth attributes.

Is Hologic (HOLX) a Solid Growth Stock? 3 Reasons to Think " Yes "

Artisan Partners Asset Management

M.D.C. Holdings

Top Ranked Growth Stocks to Buy for February 11th

ArcBest

Celestica

KB Home

Top Ranked Growth Stocks to Buy for February 9th

II-VI Incorporated

MaxLinear

Skyworks Solutions

Skyworks (SWKS), Hologic (HOLX), II-VI (IIVI) and MaxLinear (MXL) are currently witnessing a short-term pullback in price. So make sure you're taking full advantage of it.

Invest in Stocks With Momentum Anomaly for Higher Returns

Fulgent Genetics

Scientists are beginning to arrive at the notion that the fight with Covid-19 is not a short raging battle that will be over by summer 2021 but a long-term war that will be waged for many years to come, with a constant need for PPE, testing, vaccine rejiggering, specialized air filtration solutions, and other ‘coping' […]

Stocks for the Pandemic Long Haul (NASDAQ: FLGT) (OTC US: ALST) (NASDAQ: HOLX)

Does Hologic (HOLX) have what it takes to be a top stock pick for momentum investors? Let's find out.

Are You Looking for a Top Momentum Pick? Why Hologic (HOLX) is a Great Choice

Apple

Ford Motor Company

FedEx

Weyerhaeuser

At this stage, it will be prudent to invest in growth stocks with a favorable Zacks Rank. These are: AAPl, F, FDX, HOLX, WY.

5 Top-Ranked Growth Stocks to Tap Market Rally in February

Crocs

DCP Midstream

TEGNA

DCP Midstream (DCP), TEGNA (TGNA), Hologic (HOLX), Crocs (CROX) and Skyworks Solutions (SWKS) are five stocks with explosive relative price strength.

5 Relative Price Strength Stocks That Investors Will Love

MARLBOROUGH, Mass.--(BUSINESS WIRE)-- #ESG--Hologic's New Sustainability Report Highlights How the Company's Purpose-Driven Culture is Making a Unique Difference in the World

Hologic's New Sustainability Report Highlights How the Company's Purpose-Driven Culture is Making a Unique Difference in the World

"We've clearly gotten a big bump up from our Covid testing," Hologic CEO Steve Macmillan said in a "Mad Money" interview.

Diagnostics provider Hologic expects Covid-19 testing capacities to boost business post-pandemic

Anavex Life Sciences

Axsome Therapeutics

Moderna

Novavax

Cassava Sciences Inc

Meridian Bioscience

Vaxart

From vaccines to diagnostics, the opportunities in biotechnology are rich for those who do their homework.

News for Hologic Stock (HOLX)